A Multi-center, Randomized, Double-blind, Parallel, Phase 2 Clinical Trial to Compare and Evaluate the Efficacy and Safety of SPC1001 and Monotherapy in Patients With Essential Hypertension
Latest Information Update: 29 Jan 2024
At a glance
- Drugs Amlodipine/Candesartan/Indapamide (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Shin Poong Pharmaceutical
Most Recent Events
- 29 Jan 2024 New trial record